Abstract
Background:
Typically, regulatory requirements include 2 confirmatory studies, each at a 1-sided .025 significance level, for a medicine to be approved for a specific indication. When the same medicine has been approved in related indications, 1 confirmatory study at a 1-sided .025 significance level could constitute adequate evidence of efficacy for a new indication.
Methods:
This article does not contain any studies with human or animal subjects performed by any of the authors. For multiple related indications developed simultaneously to constitute sufficient evidence of clinical efficacy, the combined-studies significance level can be set at the same level as if those indications are developed sequentially.
Results:
This article establishes possible strategies to develop a few related indications at the same time for marketing registration approval, maintaining a desired combined-studies significance level; for example, 1-sided .0000156 for 2 indications, with 1 option having each indication assessed with 1 confirmatory study at .00395 significance level.
Conclusion:
It is possible to develop a few indications at the same time for marketing registration approval, where the combined-studies significance level is less stringent than that of the usual paradigm with 2 confirmatory studies each at 1-sided .025 significance level for every indication.
Keywords
Get full access to this article
View all access options for this article.
References
1.
Maca
J
Gallo
P
Branson
M
Maurer
W
. Reconsidering some aspects of the two-trial paradigm . J Biopharma Stat . 2002 ;12 :107 –109 .
2.
Shun
Z
Chi
E
Durrleman
S
Fisher
L
. Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness—one larger vs two smaller pivotal studies . Stat Med . 2005 ;24 :1619 –1637 .
3.
Fisher
LD
. One large, well-designed, multicenter study as an alternative to the usual FDA paradigm . Drug Inform J . 1999 ;33 :265 –271 .
4.
Koch
G
. Commentaries on Statistical consideration of the strategy for demonstrating clinical evidence of effectiveness—one larger vs two smaller pivotal studies . Stat Med . 2005 ;24 :1639 –1651 .
5.
US
FDA
. Guidance for industry: providing clinical evidence and effectiveness for human drug and biologic products .
Published
1998 .
6.US FDA, Center for Drug Evaluation and Research . Humira BLA 125057 approval letter, 12/31/2002 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/adalabb123102L.htm. Accessed February 3, 2018 .
7.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 10/3/2005 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/125057s0045ltr.pdf. Accessed February 3, 2018 .
8.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 11/9/2006 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/125057s071,%20s095LTR.pdf. Accessed February 3, 2018 .
9.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 7/31/2006 . https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s062lbl.pdf. Accessed February 3, 2018 .
10.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 2/27/2007 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/125057s089Ltr.pdf. Accessed February 3, 2018 .
11.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 1/18/2008 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/125057s0110ltr.pdf. Accessed February 3, 2018 .
12.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 2/21/2008 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/125057s114ltr.pdf. Accessed February 3, 2018 .
13.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 9/28/2012 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/125057Orig1s232ltr.pdf. Accessed February 3, 2018 .
14.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 9/9/2015 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125057Orig1s393ltr.pdf. Accessed February 3, 2018 .
15.US FDA, Center for Drug Evaluation and Research . Humira sBLA 125057 approval letter, 9/9/2015 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/125057Orig1s397ltr.pdf. Accessed February 3, 2018 .
16.US FDA, Center for Drug Evaluation and Research . Remicade BLA 103772 approval letter, 8/24/1998 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/inflcen082498L.htm. Accessed February 3, 2018 .
17.US FDA, Center for Drug Evaluation and Research . Remicade sBLA 103772 approval letter, 12/29/2000 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2000/inflcen122900L.htm. Accessed February 3, 2018 .
18.Center for Drug Evaluation and Research . Remicade sBLA 103772 approval letter, 2/27/2002 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/inflcen022702L.pdf. Accessed February 3, 2018 .
19.US FDA, Center for Drug Evaluation and Research . Remicade sBLA 103772 approval letter, 9/29/2004 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/103772_5073ltr.pdf. Accessed February 3, 2018 .
20.US FDA, Center for Drug Evaluation and Research . Remicade sBLA 103772 approval letter, 12/17/2004 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/103772_5077_ltr.pdf. Accessed February 3, 2018 .
21.US FDA, Center for Drug Evaluation and Research . Remicade sBLA 103772 approval letter, 5/13/2005 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/103772s5089ltr.pdf. Accessed February 3, 2018 .
22.US FDA, Center for Drug Evaluation and Research . Remicade sBLA 103772 approval letter, 9/15/2005 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/103772_5113ltr.pdf. Accessed February 3, 2018 .
23.US FDA, Center for Drug Evaluation and Research . Remicade sBLA 103772 approval letter, 8/11/2006 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2006/103772s5166s5167ltr.pdf. Accessed February 3, 2018 .
24.FDA, Center for Drug Evaluation and Research . Remicade sBLA 103772 approval letter, 9/26/2006 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/103772s5129ltr.pdf. Accessed February 3, 2018 .
25.
Cochran
WG.
Some methods for strengthening the common χ2 tests . Biometrics . 1954 ;10 (4 ):417 –451 .
26.
Mantel
N
Haenszel
W
. Statistical aspects of the analysis of data from retrospective studies of disease . J Natl Cancer Inst . 1959 ;22 (4 ):719 –748 .
27.
Fisher
RA
. Statistical Methods for Research Workers . Edinburgh : Oliver and Boyd ; 1925 .
28.
Fisher
RA
. Questions and answers #14 . Am Stat . 1948 ;2 (5 ):30 –31 .
29.
Brown
M
. A method for combining non-independent, one-sided tests of significance . Biometrics . 1975 ;31 :987 –992 .
30.
Kost
J
McDermott
M
. Combining dependent P-values . Stat Probabil Lett . 2002 ;60 :183 –190 .
31.
Mosteller
F
Bush
RR
. Selected quantitative techniques . In:
Lindzey
G
, ed. Handbook of Social Psychology , vol 1 . Cambridge, MA : Addison-Wesley ;1954 :289 –334 .
32.
Liptak
T
. On the combination of independent tests . Magyar Tud Akad Mat Kutato Int Kozl . 1958 ;3 :171 –197 .
33.US FDA, Center for Drug Evaluation and Research . Vaprisol NDA 22-016 approval letter, 2/28/2007 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/022016s000ltr.pdf. Accessed December 11, 2017 .
34.US FDA, Center for Drug Evaluation and Research. Invega NDA 22-043 approval letter, 4/27/2007 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/022043s000ltr.pdf. Accessed December 11, 2017 .
35.US FDA, Center for Drug Evaluation and Research . Lovenox NDA 22-138 approval letter, 5/16/2007 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/022138s000,020164s075ltr.pdf. Accessed December 11, 2017 .
36.US FDA, Center for Drug Evaluation and Research . Evista NDA 22-042 approval letter, 9/13/2007 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/022042s000,020815s025ltr.pdf. Accessed December 11, 2017 .
37.US FDA, Center for Drug Evaluation and Research . Seroquel XR NDA 22-172 approval letter, 11/15/2007 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2007/022172s000ltr.pdf. Accessed December 11, 2017 .
38.US FDA, Center for Drug Evaluation and Research . Luvox NDA 22-235 approval letter, 4/14/2008 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022235s000ltr.pdf. Accessed December 11, 2017 .
39.US FDA, Center for Drug Evaluation and Research . APTIVUS NDA 21-822 approval letter, 6/23/2008 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/021822s000ltr.pdf. Accessed December 11, 2017 .
40.US FDA, Center for Drug Evaluation and Research . Treanda NDA 22-303 approval letter, 10/31/2008 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/022303s000ltr.pdf. Accessed December 11, 2017 .
41.US FDA, Center for Drug Evaluation and Research . Adcirca NDA 22-332 approval letter, 5/22/2009 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022332s000ltr.pdf. Accessed December 11, 2017 .
42.US FDA, Center for Drug Evaluation and Research . Byetta NDA 21-919 approval letter, 10/30/2009 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021773s009s011s017s018s022s025021919ltr.pdf. Accessed December 11, 2017 .
43.US FDA, Center for Drug Evaluation and Research . Stivarga NDA 204369 approval letter, 2/25/2013 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204369Orig1s000ltr.pdf. Accessed December 11, 2017 .
44.US FDA, Center for Drug Evaluation and Research . Zydelig NDA 206545 approval letter, 7/23/2014 . https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/206545Orig1s000ltr.pdf. Accessed December 11, 2017 .
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
0.00 MB
0.15 MB